May 19, 2014 | Israeli company Enlivex Therapeutics has raised $7 million in a convertible loan from a group of investors. Enlivex, a portfolio company of Hadasit Bio Holdings, is developing cell immunotherapy treatments for Graft versus Host Disease.
Related posts
$10M For Cyber Company That Protects Small Businesses
January 31, 2023
Phone-Block Technology For School Bus Drivers
January 31, 2023
Israeli Patients Can Now WhatsApp Their Doctor
January 31, 2023
People With Autism Experience Higher Intensity Pain
January 30, 2023
Facebook comments